New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.
The FDA provided additional information about the agency’s interactions and decisions regarding the emergency use authorization (EUA) of Lucira Health Inc’s (OTC: LHDXQ)…
The deal covers the U.S., Canada, European Union, Great Britain, And Israel.
Avenue will also issue 831,618 shares as equity upfront and additional shares upon the achievement of a clinical milestone, aggregating
Today, the FDA Oncologic Drugs Advisory Committee is discussing the supplemental marketing application for Polivy (polatuzumab vedotin-piiq) plus Rituxan (rituximab)…
Clene Inc (NASDAQ:CLNN) announced new results from exploratory analyses, including delayed time to key clinical progression events in amyotrophic lateral sclerosis…
AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement…